A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 319 participants.

Also called NCT05785832

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 319 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05785832
Main results
  • A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes The New England journal of medicine, 2025-05-08 DOI, PubMed 40105270
Other papers using this trial's data
  • Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes Diabetes care, 2025-12-01 DOI, PubMed 41264828, PMC12635876 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level Diabetes care, 2025-12-01 DOI, PubMed 40953318, PMC13728756 Not in the PMC Open Access subset.
  • Consistent Benefit of Control-IQ+ Automated Insulin Delivery Across a Range of Characteristics of Adults with Type 2 Diabetes Diabetes technology & therapeutics, 2026-08 DOI, PubMed 41574573
  • Simplified Meal Bolus Strategies with Control-IQ+ Automated Insulin Delivery Are Safe and Effective in Adults with Type 2 Diabetes Diabetes technology & therapeutics, 2026-05 DOI, PubMed 41264341

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05785832. Randomized; no masking; primary purpose treatment. Start 2023-06-01 (actual); primary completion 2024-09-24 (actual). Results posted on 2025-06-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes
Acronym
2IQP
Condition
Type 2 Diabetes Treated With Insulin
Intervention (Device)
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM
Intervention (Device)
Standard Therapy plus continuous glucose monitoring (CGM)
Lead sponsor
Tandem Diabetes Care, Inc. (class: industry)
Collaborator
Jaeb Center for Health Research (class: other)

Record details

Record id
cardio:ct-nct05785832
Content hash
f8415afac692cd962920bd8944903924c8b639f999fd29fc9e00822a16c987bd